Key figures – 3rd quarter 2010 |
|
|
|
|
|
|
|
|
|
|
|
EUR million |
Pharma- |
Chemicals |
Corporate |
Total |
Change |
Total revenues |
1,518.4 |
919.4 |
– |
2,437.8 |
25.0 |
Gross margin |
1,286.0 |
532.1 |
– |
1,818.2 |
27.3 |
Research and development |
–285.1 |
–63.5 |
– |
–348.6 |
4.7 |
Operating result |
225.7 |
161.8 |
–24.1 |
363.5 |
63.6 |
Exceptional items |
– |
– |
– |
– |
– |
Earnings before interest and tax (EBIT) |
225.7 |
161.8 |
–24.1 |
363.5 |
63.6 |
EBIT before depreciation and amortization (EBITDA) |
423.4 |
301.2 |
–22.9 |
701.7 |
54.0 |
Return on sales in % |
14.9 |
17.6 |
– |
14.9 |
|
Free cash flow |
418.1 |
–4,673.0 |
–127.9 |
–4,382.9 |
– |
Underlying free cash flow |
418.1 |
267.3 |
–124.6 |
560.7 |
30.6 |
Underlying free cash flow |
27.5 |
29.1 |
– |
23.0 |
|
